Key Highlights from EV-302 Study at ESMO 2023
Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
Sia Daneshmand Radical Cystectomy Metastatic Disease Chemo Radiation Platinum Based Therapies Ev 302 Study
Source: ajmc.com